Cargando…

Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus

BACKGROUND: The present study investigates the efficacy in glycemic control by adding once-a-day glulisine to glargine as a basal plus regimen and factors influencing glycemic control with the basal plus regimen in Korean subjects with type 2 diabetes. METHODS: In the present retrospective study, su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choe, Eun Yeong, Lee, Yong-ho, Lee, Byung-Wan, Kang, Eun-Seok, Cha, Bong Soo, Lee, Hyun Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380127/ https://www.ncbi.nlm.nih.gov/pubmed/22737663 http://dx.doi.org/10.4093/dmj.2012.36.3.230

Ejemplares similares

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
por: Wang, Fei, et al.
Publicado: (2012)

Clinical Characteristics of Patients Responding to Once-Daily Basal Insulin Therapy in Korean Subjects with Type 2 Diabetes
por: Song, Sun Ok, et al.
Publicado: (2015)

The metabolic and mitogenic properties of basal insulin analogues
por: Tennagels, Norbert, et al.
Publicado: (2013)

The glycemic efficacies of insulin analogue regimens according to baseline glycemic status in Korean patients with type 2 diabetes: sub-analysis from the A(1)chieve® study
por: Hwang, Y-C, et al.
Publicado: (2014)

Characteristics Predictive for a Successful Switch from Insulin Analogue Therapy to Oral Hypoglycemic Agents in Patients with Type 2 Diabetes
por: Kim, Gyuri, et al.
Publicado: (2016)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

Safety and Efficacy of Modern Insulin Analogues
por: Yoo, Hye Jin, et al.
Publicado: (2013)

Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes
por: Nicolucci, Antonio, et al.
Publicado: (2019)

Replacement of neutral protamine Hagedorn insulin with the long‐acting insulin analogue, detemir, improves glycemic control without weight gain in basal–bolus insulin therapy in Japanese patients with type 1 diabetes
por: Hayakawa, Taro, et al.
Publicado: (2011)

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
por: Jang, Han Na, et al.
Publicado: (2019)

Budget Impact of Long-Acting Insulin Analogues: The Case in Brazil
por: Laranjeira, Fernanda O, et al.
Publicado: (2016)

Molecular Characterisation of Long-Acting Insulin Analogues in Comparison with Human Insulin, IGF-1 and Insulin X10
por: Hansen, Bo F., et al.
Publicado: (2012)

Potential Role of Ultrafast-acting Insulin Analogues in the Treatment of Diabetic Ketoacidosis
por: Koufakis, Theocharis, et al.
Publicado: (2022)

Engineering of Insulin Receptor Isoform-Selective Insulin Analogues
por: Glendorf, Tine, et al.
Publicado: (2011)

Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made?
por: Kalra, Sanjay
Publicado: (2015)

Combination Therapy With Premixed & Basal Insulin Analogues in Asian Indians With Type 2 Diabetes
por: Srivastava, Brijendra Kumar, et al.
Publicado: (2021)

Cardioprotective role of insulin: Advantage analogues
por: Maiti, Rituparna, et al.
Publicado: (2012)

Immunologic Tolerance to the Insulin Analogue Glulisine
por: Ozaki, Nobuaki, et al.
Publicado: (2010)

Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia
por: Buturovic, Belma Ascic, et al.
Publicado: (2014)

Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial
por: Bue-Valleskey, Juliana M., et al.
Publicado: (2023)

Therapeutics of Diabetes Mellitus: Focus on Insulin Analogues and Insulin Pumps
por: Valla, Vasiliki
Publicado: (2010)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014)

Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
por: Lim, Beng Leong, et al.
Publicado: (2023)

Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
por: Hartmann, Thorsten, et al.
Publicado: (2016)

Current european regulatory perspectives on insulin analogues
por: Enzmann, Harald G, et al.
Publicado: (2011)

Review of Insulin and its Analogues in Diabetes Mellitus
por: Mane, Krishnappa, et al.
Publicado: (2012)

Degludec: the new ultra-long insulin analogue
por: Tambascia, Marcos Antonio, et al.
Publicado: (2015)

Characterisation of insulin analogues therapeutically available to patients
por: Adams, Gary G., et al.
Publicado: (2018)

Chymotrypsin substrate analogues inhibit endocytosis of insulin and insulin receptors in adipocytes
Publicado: (1986)

Production costs and potential prices for biosimilars of human insulin and insulin analogues
por: Gotham, Dzintars, et al.
Publicado: (2018)

Human Insulin Versus Insulin Analogues: A True Companion Forgotten
por: Abdi, Hengameh
Publicado: (2019)

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes
por: Bergenstal, Richard M., et al.
Publicado: (2012)

Efficacy and Safety of Treatment with New Basal Insulin Analogues in Type 1 Diabetes: Nation-Wide Survey
por: Svensson, Ann-Marie, et al.
Publicado: (2020)

Counselling Patients for GLP-1 Analogue Therapy: Comparing GLP-1 Analogue with Insulin Counselling
por: Kalra, Sanjay, et al.
Publicado: (2012)

Preclinical Characterization of Once Weekly Basal Insulin Fc (BIF)
por: Moyers, Julie S, et al.
Publicado: (2021)

Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications
por: Godman, Brian, et al.
Publicado: (2021)

A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes
por: Yang, Chun-Ting, et al.
Publicado: (2021)

Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes
por: Kazda, Christof M., et al.
Publicado: (2023)

Determination of amyloid core regions of insulin analogues fibrils
por: Surin, Alexey K., et al.
Publicado: (2020)

Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues
por: Vaag, Allan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6jgg77mv0tlklj9942bl32gdhk